Wells Fargo
AVBP icon

Wells Fargo’s ArriVent BioPharma AVBP Stock Holding History

Wells Fargo’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$280K Sell
12,124
-20,156
-62% -$455K ﹤0.01% 4490
2025
Q4 		$649K Buy
32,280
+17,101
+113% +$356K ﹤0.01% 4293
2025
Q3 		$280K Buy
15,179
+3,276
+28% +$64.4K ﹤0.01% 4724
2025
Q2 		$259K Sell
11,903
-2,916
-20% -$60.5K ﹤0.01% 4616
2025
Q1 		$274K Buy
14,819
+326
+2% +$7.98K ﹤0.01% 4483
2024
Q4 		$386K Buy
14,493
+4,139
+40% +$119K ﹤0.01% 4355
2024
Q3 		$243K Buy
10,354
+6,751
+187% +$153K ﹤0.01% 4449
2024
Q2 		$66.8K Buy
3,603
+372
+12% +$6.63K ﹤0.01% 5166
2024
Q1 		$57.7K Buy
+3,231
New +$65.2K ﹤0.01% 5197

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wells Fargo's AVBP Position: Q1 2026 in Review

Wells Fargo reduced its ArriVent BioPharma (AVBP) stake by 62% in Q1 2026, selling an estimated $455K and leaving 12,124 shares worth $280K. The position accounts for ﹤0.01% of the portfolio, ranked #4490.

Wells Fargo first reported a position in AVBP in Q1 2024 and has held it in 9 quarters since. The position peaked at $649K in Q4 2025. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Wells Fargo held 12,124 shares of ArriVent BioPharma worth $280K as of Q1 2026.
  • Wells Fargo sold 20,156 ArriVent BioPharma shares in Q1 2026, an estimated $455K.
  • ArriVent BioPharma made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4490 holding.
  • Wells Fargo first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 9 quarters since.
  • Wells Fargo's ArriVent BioPharma position peaked at $649K in Q4 2025.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.